1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
|
2
|
Wein AJ, Kavoussi LR, Novick AC, Partin AW
and Peters CA: Campbell-Walsh Urology. 9th edition. Saunders
Elsevier; Philadelphia: 2007
|
3
|
Levy DA, Slaton JW, Swanson DA and Dinney
CP: Stage specific guidelines for surveillance after radical
nephrectomy for local renal cell carcinoma. J Urol. 159:1163–1167.
1998. View Article : Google Scholar : PubMed/NCBI
|
4
|
Eble JN, Epstein JI and Sesterhenn IA:
World Health Organization classification of tumors. IARC Press;
Lyon: 2004
|
5
|
Kim HL, Seligson D, Liu X, et al: Using
protein expressions to predict survival in clear cell renal
carcinoma. Clin Cancer Res. 10:5464–5471. 2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
7
|
Clarke MF, Dick JE, Dirks PB, et al:
Cancer stem cells – perspectives on current status and future
directions: AACR Workshop on cancer stem cells. Cancer Res.
66:9339–9344. 2006.
|
8
|
Burkert J, Wright NA and Alison MR: Stem
cells and cancer: an intimate relationship. J Pathol. 209:287–297.
2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Brabletz T, Jung A, Spaderna S, Hlubek F
and Kirchner T: Opinion: migrating cancer stem cells – an
integrated concept of malignant tumour progression. Nat Rev Cancer.
5:744–749. 2005.PubMed/NCBI
|
10
|
Miraglia S, Godfrey W, Yin AH, et al: A
novel five-transmembrane hematopoietic stem cell antigen:
isolation, characterization, and molecular cloning. Blood.
90:5013–5021. 1997.PubMed/NCBI
|
11
|
Mizrak D, Brittan M and Alison MR: CD133:
molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Horst D, Kriegl L, Engel J, Kirchner T and
Jung A: Prognostic significance of the cancer stem cell markers
CD133, CD44, and CD166 in colorectal cancer. Cancer Invest.
27:844–850. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Wang Q, Chen ZG, Du CZ, Wang HW, Yan L and
Gu J: Cancer stem cell marker CD133+ tumour cells and clinical
outcome in rectal cancer. Histopathology. 55:284–293. 2009.
|
14
|
Kojima M, Ishii G, Atsumi N, Fujii S,
Saito N and Ochiai A: Immunohistochemical detection of CD133
expression in colorectal cancer: a clinicopathological study.
Cancer Sci. 99:1578–1583. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Bussolati B, Bruno S, Grange C, et al:
Isolation of renal progenitor cells from adult human kidney. Am J
Pathol. 166:545–555. 2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
Florek M, Haase M, Marzesco AM, et al:
Prominin-1/CD133, a neural and hematopoietic stem cell marker, is
expressed in adult human differentiated cells and certain types of
kidney cancer. Cell Tissue Res. 319:15–26. 2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
Cheville JC, Lohse CM, Zincke H, Weaver AL
and Blute ML: Comparisons of outcome and prognostic features among
histologic subtypes of renal cell carcinoma. Am J Surg Pathol.
27:612–624. 2003. View Article : Google Scholar : PubMed/NCBI
|
18
|
Cheng L, Sung MT, Cossu-Rocca P, et al:
OCT4: biological functions and clinical applications as a marker of
germ cell neoplasia. J Pathol. 211:1–9. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Jones TD, Ulbright TM, Eble JN and Cheng
L: OCT4: a sensitive and specific biomarker for intratubular germ
cell neoplasia of the testis. Clin Cancer Res. 10:8544–8547. 2004.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Lengner CJ, Welstead GG and Jaenisch R:
The pluripotency regulator Oct4: a role in somatic stem cells? Cell
Cycle. 7:725–728. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
22
|
Greene FL and Fleming ID: AJCC Cancer
Staging Manual. 6th edition. Springer-Verlag; Chicago: 2002,
View Article : Google Scholar
|
23
|
Kim K, Lee KM, Han DJ, Yu E and Cho YM:
Adult stem cell-like tubular cells reside in the corticomedullary
junction of the kidney. Int J Clin Exp Pathol. 1:232–241.
2008.PubMed/NCBI
|
24
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Tirino V, Camerlingo R, Franco R, et al:
The role of CD133 in the identification and characterisation of
tumour-initiating cells in non-small-cell lung cancer. Eur J
Cardiothorac Surg. 36:446–453. 2009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Rutella S, Bonanno G, Procoli A, et al:
Cells with characteristics of cancer stem/progenitor cells express
the CD133 antigen in human endometrial tumors. Clin Cancer Res.
15:4299–4311. 2009. View Article : Google Scholar : PubMed/NCBI
|
27
|
Yin AH, Miraglia S, Zanjani ED, et al:
AC133, a novel marker for human hematopoietic stem and progenitor
cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
|
28
|
O’Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110.
2007.PubMed/NCBI
|
29
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human
colon-cancer-initiating cells. Nature. 445:111–115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Zeppernick F, Ahmadi R, Campos B, et al:
Stem cell marker CD133 affects clinical outcome in glioma patients.
Clin Cancer Res. 14:123–129. 2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Artells R, Moreno I, Diaz T, et al: Tumour
CD133 mRNA expression and clinical outcome in surgically resected
colorectal cancer patients. Eur J Cancer. 46:642–649. 2010.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Todaro M, Alea MP, Di Stefano AB, et al:
Colon cancer stem cells dictate tumor growth and resist cell death
by production of interleukin-4. Cell Stem Cell. 1:389–402. 2007.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Bao S, Wu Q, McLendon RE, et al: Glioma
stem cells promote radioresistance by preferential activation of
the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
34
|
Woodward WA, Chen MS, Behbod F, Alfaro MP,
Buchholz TA and Rosen JM: WNT/beta-catenin mediates radiation
resistance of mouse mammary progenitor cells. Proc Natl Acad Sci
USA. 104:618–623. 2007. View Article : Google Scholar : PubMed/NCBI
|
35
|
Chiou SH, Kao CL, Chen YW, et al:
Identification of CD133-positive radioresistant cells in atypical
teratoid/rhabdoid tumor. PLoS One. 3:e20902008. View Article : Google Scholar : PubMed/NCBI
|
36
|
Smith LM, Nesterova A, Ryan MC, et al:
CD133/prominin-1 is a potential therapeutic target for
antibody-drug conjugates in hepatocellular and gastric cancers. Br
J Cancer. 99:100–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
37
|
Ferrandina G, Martinelli E, Petrillo M, et
al: CD133 antigen expression in ovarian cancer. BMC Cancer.
9:2212009. View Article : Google Scholar : PubMed/NCBI
|
38
|
Piras F, Perra MT, Murtas D, et al: The
stem cell marker nestin predicts poor prognosis in human melanoma.
Oncol Rep. 23:17–24. 2010.PubMed/NCBI
|
39
|
Bruno S, Bussolati B, Grange C, et al:
CD133+ renal progenitor cells contribute to tumor
angiogenesis. Am J Pathol. 169:2223–2235. 2006.
|
40
|
Corbeil D, Roper K, Hellwig A, et al: The
human AC133 hematopoietic stem cell antigen is also expressed in
epithelial cells and targeted to plasma membrane protrusions. J
Biol Chem. 275:5512–5520. 2000. View Article : Google Scholar : PubMed/NCBI
|
41
|
Fargeas CA, Joester A, Missol-Kolka E,
Hellwig A, Huttner WB and Corbeil D: Identification of novel
Prominin-1/CD133 splice variants with alternative C-termini and
their expression in epididymis and testis. J Cell Sci.
117:4301–4311. 2004. View Article : Google Scholar : PubMed/NCBI
|
42
|
Giebel B, Corbeil D, Beckmann J, et al:
Segregation of lipid raft markers including CD133 in polarized
human hematopoietic stem and progenitor cells. Blood.
104:2332–2338. 2004. View Article : Google Scholar : PubMed/NCBI
|
43
|
Weigmann A, Corbeil D, Hellwig A and
Huttner WB: Prominin, a novel microvilli-specific polytopic
membrane protein of the apical surface of epithelial cells, is
targeted to plasmalemmal protrusions of non-epithelial cells. Proc
Natl Acad Sci USA. 94:12425–12430. 1997. View Article : Google Scholar
|
44
|
Corbeil D, Roper K, Fargeas CA, Joester A
and Huttner WB: Prominin: a story of cholesterol, plasma membrane
protrusions and human pathology. Traffic. 2:82–91. 2001. View Article : Google Scholar : PubMed/NCBI
|
45
|
Rousseau A, Ayoubi F, Deveaux C, et al:
Impact of age and gender interaction on circulating endothelial
progenitor cells in healthy subjects. Fertil Steril. 93:843–846.
2010. View Article : Google Scholar : PubMed/NCBI
|
46
|
Lemieux C, Cloutier I and Tanguay JF:
Menstrual cycle influences endothelial progenitor cell regulation:
a link to gender differences in vascular protection? Int J Cardiol.
136:200–210. 2009. View Article : Google Scholar : PubMed/NCBI
|